Top

Breast Cancer Research

Published in:

Open Access 01-12-2022 | Breast Cancer | Research

MiRNA expression deregulation correlates with the Oncotype DX^® DCIS score

Authors: Olivier Loudig, Megan I. Mitchell, Iddo Z. Ben-Dov, Christina Liu, Susan Fineberg

Published in: Breast Cancer Research | Issue 1/2022

Abstract

Background

Current clinical criteria do not discriminate well between women who will or those who will not develop ipsilateral invasive breast cancer (IBC), or a DCIS recurrence after a ductal carcinoma in situ (DCIS) diagnosis. The 12-gene Oncotype DX® DCIS assay (RT qPCR gene-based scoring system) was established and shown to predict the risk of subsequent ipsilateral IBC or DCIS recurrence. Recent studies have shown that microRNA (miRNA) expression deregulation can contribute to the development of IBC, but very few have evaluated miRNA deregulation in DCIS lesions. In this study, we sought to determine whether specific miRNA expression changes may correlate with Oncotype DX® DCIS scores.

Methods

For this study, we used archived formalin-fixed, paraffin-embedded (FFPE) specimens from 41 women diagnosed with DCIS between 2012 and 2018. The DCIS lesions were stratified into low (n = 26), intermediate (n = 10), and high (n = 5) risk score groups using the Oncotype DX® DCIS assay. Total RNA was extracted from DCIS lesions by macro-dissection of unstained FFPE sections, and next-generation small-RNA sequencing was performed. We evaluated the correlation between miRNA expression data and Oncotype score, as well as patient age. RT-qPCR validations were performed to validate the topmost differentially expressed miRNAs identified between the different risk score groups.

Results

MiRNA sequencing of 32 FFPE DCIS specimens from the three different risk group scores identified a correlation between expression deregulation of 17 miRNAs and Oncotype scores. Our analyses also revealed a correlation between the expression deregulation of 9 miRNAs and the patient’s age. Based on these results, a total of 15 miRNAs were selected for RT-qPCR validation. Of these, miR-190b (p = 0.043), miR-135a (p = 0.05), miR-205 (p = 0.00056), miR-30c (p = 0.011), and miR-744 (p = 0.038) showed a decreased expression in the intermediate/high Oncotype group when compared to the low-risk score group. A composite risk score was established using these 5 miRNAs and indicated a significant association between miRNA expression deregulation and the Oncotype DX® DCIS Score (p < 0.0021), between high/intermediate and low risk groups.

Conclusions

Our analyses identified a subset of 5 miRNAs able to discriminate between Oncotype DX® DCIS score subgroups. Together, our data suggest that miRNA expression analysis may add value to the predictive and prognostic evaluation of DCIS lesions.

Available only for authorised users

Vaidya Y, Vaidya P, Vaidya T. Ductal carcinoma in situ of the breast. Indian J Surg. 2015;77(2):141–6. https://doi.org/10.1007/s12262-013-0987-0 (Epub 2013 Oct 12. PMID: 26139969; PMCID: PMC4484537).CrossRefPubMed

Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010;41:134–8.CrossRef

Ward WH, DeMora L, Handorf E, et al. Preoperative delays in the treatment of DCIS and the associated incidence of invasive breast cancer. Ann Surg Oncol. 2020;27:386–96. https://doi.org/10.1245/s10434-019-07844-4.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442 (Epub 2018 Jan 4 PMID: 29313949).CrossRefPubMed

Kong J, Liu X, Zhang X, Zou Y. The predictive value of calcification for the grading of ductal carcinoma in situ in Chinese patients. Medicine (Baltimore). 2020;99(28):e20847. https://doi.org/10.1097/MD.0000000000020847 (PMID:32664078;PMCID:PMC7360308).CrossRef

Sundara Rajan S, Verma R, Shaaban AM, Sharma N, Dall B, Lansdown M. Palpable ductal carcinoma in situ: analysis of radiological and histological features of a large series with 5-year follow-up. Clin Breast Cancer. 2013;13(6):486–91. https://doi.org/10.1016/j.clbc.2013.08.002 (PMID: 24267733).CrossRefPubMed

Gooch JC, Chun J, Kaplowitz E, Kurz E, Guth A, Lee J, Schnabel F. Breast density in a contemporary cohort of women with ductal carcinoma in situ (DCIS). Ann Surg Oncol. 2019;26(11):3472–7. https://doi.org/10.1245/s10434-019-07479-5 (Epub 2019 May 30 PMID: 31147991).CrossRefPubMed

Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–44.CrossRef

Wang LC, Sullivan M, Du H, Feldman MI, Mendelson EB. US appearance of ductal carcinoma in situ. Radiographics. 2013;33(1):213–28. https://doi.org/10.1148/rg.331125092.CrossRefPubMed

10.

Parikh U, Chhor CM, Mercado CL. Ductal carcinoma in situ: the whole truth. AJR Am J Roentgenol. 2018;210(2):246–55. https://doi.org/10.2214/AJR.17.18778.CrossRefPubMed

11.

Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol biomark prev publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2005;14(4):1008–11. https://doi.org/10.1158/1055-9965.EPI-04-0849.CrossRef

12.

Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170–8. https://doi.org/10.1093/jnci/djp482 (Epub 2010 Jan 13 PMID: 20071685).CrossRefPubMed

13.

Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76(7):1197–200 (PMID: 8630897).CrossRef

14.

Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 2005;103(9):1778–84. https://doi.org/10.1002/cncr.20979 (PMID: 15770688).CrossRefPubMed

15.

Williams KE, Barnes NLP, Cramer A, Johnson R, Cheema K, Morris J, Howe M, Bundred NJ. Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol. 2015;26(5):1019–25. https://doi.org/10.1093/annonc/mdv062 (Epub 2015 Feb 12 PMID: 25678586).CrossRefPubMed

16.

Giannakeas V, Sopik V, Narod SA. A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. Breast Cancer Res Treat. 2018;169(3):587–94. https://doi.org/10.1007/s10549-018-4716-z.CrossRefPubMed

17.

Giannakeas V, Sopik V, Narod SA. Association of a diagnosis of ductal carcinoma in situ with death from breast cancer. JAMA Netw Open. 2020;3(9):e2017124. https://doi.org/10.1001/jamanetworkopen.2020.17124.CrossRefPubMedPubMedCentral

18.

Tavassoli FA. Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification. Nat Clin Pract Oncol. 2005;2(3):116–7. https://doi.org/10.1038/ncponc0109 (PMID: 16264885).CrossRefPubMed

19.

Pinder SE. Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol. 2010;23(Suppl 2):S8-13. https://doi.org/10.1038/modpathol.2010.40 (PMID: 20436505).CrossRefPubMed

20.

Zhang X, Dai H, Liu B, Song F, Chen K. Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis. Eur J Cancer Prev. 2016;25(1):19–28. https://doi.org/10.1097/CEJ.0000000000000131 (PMID:25714649;PMCID:PMC4885540).CrossRefPubMed

21.

Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481–4. https://doi.org/10.1002/cncr.21069 (PMID: 15884091).CrossRefPubMed

22.

Yeong J, Thike AA, Tan PH, Iqbal J. Identifying progression predictors of breast ductal carcinoma in situ. J Clin Pathol. 2017;70(2):102–8. https://doi.org/10.1136/jclinpath-2016-204154 (Epub 2016 Nov 18 PMID: 27864452).CrossRefPubMed

23.

Correa C, McGale P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;41:162–77.

24.

Giannakeas V, Sopik V, Narod SA. Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy. JAMA Netw Open. 2018;1(4):e181100.CrossRef

25.

Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28:3762–9.CrossRef

26.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627–37. https://doi.org/10.1093/jnci/djq101.CrossRefPubMedPubMedCentral

27.

Solin LJ, et al. A Multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10.CrossRef

28.

Whitney J, Corredor G, Janowczyk A, Ganesan S, Doyle S, Tomaszewski J, Feldman M, Gilmore H, Madabhushi A. Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer. BMC Cancer. 2018;18(1):610. https://doi.org/10.1186/s12885-018-4448-9 (PMID:29848291;PMCID:PMC5977541).CrossRefPubMedPubMedCentral

29.

Durrani S, Al-Mushawa F, Heena H, Wani T, Al-Qahtani A. Relationship of oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and nottingham prognostic index in early breast cancer tumors in Saudi population. Ann Diagn Pathol. 2021;51:151674. https://doi.org/10.1016/j.anndiagpath.2020.151674.CrossRefPubMed

30.

Huang Z, Qin Q, Xia L, Lian B, Tan Q, Yu Y, Mo Q. significance of oncotype DX 21-gene test and expression of long non-coding RNA MALAT1 in early and estrogen receptor-positive breast cancer patients. Cancer Manag Res. 2021;22(13):587–93. https://doi.org/10.2147/CMAR.S276795 (PMID:33519238;PMCID:PMC7837574).CrossRef

31.

Baehner FL. The analytical validation of the oncotype DX Recurrence Score assay. Ecancermedicalscience. 2016;26(10):675. https://doi.org/10.3332/ecancer.2016.675 (PMID:27729940;PMCID:PMC5045300).CrossRef

32.

Pennock ND, Jindal S, Horton W, Sun D, Narasimhan J, Carbone L, Fei SS, Searles R, Harrington CA, Burchard J, Weinmann S, Schedin P, Xia Z. RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery. BMC Med Genomics. 2019;12(1):195. https://doi.org/10.1186/s12920-019-0643-z (PMID:31856832;PMCID:PMC6924022).CrossRefPubMedPubMedCentral

33.

Cohen PA, Loudig O, Liu C, Albanese J, Fineberg S. The ZNF217 biomarker predicts low- and high-risk oncotype DX® recurrence score in ER-positive invasive breast cancers. Front Pharmacol. 2019;28(10):524. https://doi.org/10.3389/fphar.2019.00524 (PMID:31191299;PMCID:PMC6546897).CrossRef

34.

Nofech-Mozes S, Hanna W, Rakovitch E. Molecular evaluation of breast ductal carcinoma in situ with oncotype DX DCIS. Am J Pathol. 2019;189(5):975–80. https://doi.org/10.1016/j.ajpath.2018.12.003.CrossRefPubMed

35.

Paszat L, Sutradhar R, Zhou L, Nofech-Mozes S, Rakovitch E. Including the ductal carcinoma in situ (DCIS) Score in the development of a multivariable prediction model for recurrence after excision of DCIS. Clin Breast Cancer. 2018;19:35–46.CrossRef

36.

Rakovitch E, Gray R, Baehner FL, et al. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat. 2018;169:359–69.CrossRef

37.

Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell Press. 2004;116:281–97.

38.

Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans. 2008;36(Pt 6):1224–31. https://doi.org/10.1042/BST0361224 (PMID: 19021530).CrossRefPubMed

39.

Hobert O. Gene regulation by transcription factors and microRNAs. Science. 2008;319(5871):1785–6. https://doi.org/10.1126/science.1151651 (PMID: 18369135).CrossRefPubMed

40.

Gong X, Sun J, Zhao Z. Gene regulation in glioblastoma: a combinatorial analysis of microRNAs and transcription factors. Int J Comput Biol Drug Des. 2011;4(2):111–26. https://doi.org/10.1504/IJCBDD.2011.041006 (Epub 2011 Jun 28 PMID: 21712563).CrossRefPubMed

41.

Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58–63. https://doi.org/10.1038/nature07228 (Epub 2008 Jul 30 PMID: 18668040).CrossRefPubMed

42.

Uhlmann S, Mannsperger H, Zhang JD, Horvat EÁ, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, Sahin O. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol. 2012;14(8):570. https://doi.org/10.1038/msb.2011.100 (PMID:22333974;PMCID:PMC3293631).CrossRef

43.

York A, Teo T, et al. Tiny MiRNAs play a big role in the treatment of breast cancer metastasis. Cancers. 2021;13(2):337.CrossRef

44.

Hannafon BN, Ding WQ. MiRNAs as biomarkers for predicting the progression of ductal carcinoma in situ. Am J Pathol. 2018;188(3):542–9. https://doi.org/10.1016/j.ajpath.2017.11.003.CrossRefPubMedPubMedCentral

45.

Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.CrossRef

46.

Loudig O, Milova E, Brandwein-Gensler M, Massimi A, Belbin TJ, Childs G, Singer RH, Rohan T, Prystowsky MB. Molecular restoration of archived transcriptional profiles by complementary-template reverse-transcription (CT-RT). Nucleic Acids Res. 2007;35(15):e94. https://doi.org/10.1093/nar/gkm510.CrossRefPubMedPubMedCentral

47.

Loudig O, Brandwein-Gensler M, Kim RS, Lin J, Isayeva T, Liu C, Segall JE, Kenny PA, Prystowsky MB. Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma. Hum Pathol. 2011;42(12):1911–22. https://doi.org/10.1016/j.humpath.2011.02.011.CrossRefPubMed

48.

Loudig Ol, et al. Evaluation and adaptation of a laboratory-based CDNA library preparation protocol for retrospective sequencing of archived MicroRNAs from up to 35-year-old clinical FFPE specimens. Int J Mol Sci. 2017;18(3):627.CrossRef

49.

Loudig O, Liu C, Rohan T, Ben-Dov IZ. Retrospective MicroRNA sequencing: complementary DNA library preparation protocol using formalin-fixed paraffin-embedded RNA specimens. J Vis Exp JoVE. 2018;135:57471. https://doi.org/10.3791/57471.CrossRef

50.

Kotorashvili A, Ramnauth A, Liu C, Lin J, Ye K, Kim R, Hazan R, Rohan T, Fineberg S, Loudig O. Effective DNA/RNA co-extraction for analysis of microRNAs, mRNAs, and genomic DNA from formalin-fixed paraffin-embedded specimens. PLoS One. 2012;7(4):e34683. https://doi.org/10.1371/journal.pone.0034683.CrossRefPubMedPubMedCentral

51.

Mazeh H, Deutch T, Karas A, Bogardus KA, Mizrahi I, Gur-Wahnon D, Ben-Dov IZ. Next-generation sequencing identifies a highly accurate miRNA Panel that distinguishes well-differentiated thyroid cancer from benign thyroid nodules. Cancer Epidemiol Biomarkers Prev. 2018;27(8):858–63. https://doi.org/10.1158/1055-9965 (EPI-18-400055 PMID: 30049841).CrossRefPubMed

52.

Ryser MD, Hendrix LH, Worni M, Liu Y, Hyslop T, Hwang ES. Incidence of ductal carcinoma in situ in the United States, 2000–2014. Cancer Epidemiol Biomark Prev. 2019;28(8):1316–23. https://doi.org/10.1158/1055-9965 (EPI-18-1262 Epub 2019 Jun 11. PMID: 31186262; PMCID: PMC6679771).CrossRef

53.

54.

Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, Leesman G, Linke SP, Jirström K, Zhou W, Amini RM, Wärnberg F. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24(23):5895–901. https://doi.org/10.1158/1078-0432.CCR-18-0842 (Epub 2018 Jul 27 PMID: 30054280).CrossRefPubMed

55.

Bergholtz H, Lien TG, Swanson DM, et al. Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions. npj Breast Cancer. 2020;6:26. https://doi.org/10.1038/s41523-020-0167-x.CrossRefPubMedPubMedCentral

56.

Siow ZR, De Boer RH, Lindeman GJ, Mann GB. Spotlight on the utility of the oncotype DX® breast cancer assay. Int J Womens Health. 2018;21(10):89–100. https://doi.org/10.2147/IJWH.S124520 (PMID:29503586;PMCID:PMC5827461).CrossRef

57.

Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, Veronese A, Fabbri M, Carasi S, Alder H, Lanza G, Gafa’ R, Moyer MP, Ridgway RA, Cordero J, Nuovo GJ, Frankel WL, Rugge M, Fassan M, Groden J, Vogt PK, Karin M, Sansom OJ, Croce CM. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell. 2014;25(4):469–83. https://doi.org/10.1016/j.ccr.2014.03.006 (PMID:24735923;PMCID:PMC3995091).CrossRefPubMedPubMedCentral

58.

Zhang YJ, Ma YS, Xia Q, Yu F, Lv ZW, Jia CY, Jiang XX, Zhang L, Shao YC, Xie WT, Lu GX, Yv XQ, Zhong P, Fu D, Wang XF. MicroRNA-mRNA integrated analysis based on a case of well-differentiated thyroid cancer with both metastasis and metastatic recurrence. Oncol Rep. 2018;40(6):3803–11. https://doi.org/10.3892/or.2018.6739 (Epub 2018 Sep 26 PMID: 30272320).CrossRefPubMed

59.

Zuberi M, Mir R, Khan I, Javid J, Guru SA, Bhat M, Sumi MP, Ahmad I, Masroor M, Yadav P, Vishnubhatla S, Saxena A. The promising signatures of circulating microRNA-145 in epithelial ovarian cancer patients. Microrna. 2020;9(1):49–57. https://doi.org/10.2174/2211536608666190225111234 (PMID: 30799804).CrossRefPubMed

60.

Zou MX, Huang W, Wang XB, Lv GH, Li J, Deng YW. Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma. Int J Clin Exp Pathol. 2014;7(8):4877–85.PubMedPubMedCentral

61.

Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD. Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer. Mol Oncol. 2017;11(2):220–34. https://doi.org/10.1002/1878-0261.12025.CrossRefPubMed

62.

Quan Y, Huang X, Quan X. Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis. Oncol Lett. 2018;16(5):6638–42. https://doi.org/10.3892/ol.2018.9440 (Epub 2018 Sep 17. PMID: 30405803; PMCID: PMC6202535).CrossRefPubMedPubMedCentral

63.

Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: a miRNA expression analysis. Gene. 2018;5(673):181–93. https://doi.org/10.1016/j.gene.2018.06.037 (Epub 2018 Jun 18 PMID: 29913239).CrossRef

64.

Zhang YH, Jin M, Li J, Kong X. Identifying circulating miRNA biomarkers for early diagnosis and monitoring of lung cancer. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165847. https://doi.org/10.1016/j.bbadis.2020.165847 (Epub 2020 May 27. PMID: 32473385).CrossRefPubMed

65.

Cao Z, Qiu J, Yang G, Liu Y, Luo W, You L, Zheng L, Zhang T. MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy. Cancer Biol Med. 2020;17(3):569–82. https://doi.org/10.20892/j.issn.2095-3941.2020.0033.CrossRefPubMedPubMedCentral

66.

Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M, Teal CB, Brem RF, Stojadinovic A, Grinkemeyer M, McCaffrey TA, Man YG, Fu SW. Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One. 2013;8(1):e54213. https://doi.org/10.1371/journal.pone.0054213.CrossRefPubMedPubMedCentral

67.

Qi L, Bart J, Tan LP, Platteel I, Sluis TV, Huitema S, Harms G, Fu L, Hollema H, Berg AV. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163. https://doi.org/10.1186/1471-2407-9-163.CrossRefPubMedPubMedCentral

68.

Li S, Pu T, Xiao L, Gao H, Li L, Ye F, Liu Y, Bu H. Screening of recurrence related MicroRNA in ductal carcinoma in situ and functional study of MicroRNA-654-5p. J Breast Cancer. 2019;22(1):52–66. https://doi.org/10.4048/jbc.2019.22.e4.CrossRefPubMedPubMedCentral

69.

Hannafon BN, Sebastiani P, de las Morenas A, Lu J, Rosenberg CL. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res BCR. 2011;13(2):R24. https://doi.org/10.1186/bcr2839.CrossRefPubMed

70.

Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S, Cole CN. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Can Res. 2007;67(24):11612–20.CrossRef

71.

Cizeron-Clairac G, Lallemand F, Vacher S, Lidereau R, Bieche I, Callens C. MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers? BMC Cancer. 2015;15:499. https://doi.org/10.1186/s12885-015-1505-5.CrossRefPubMedPubMedCentral

72.

Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(1):43–51. https://doi.org/10.1007/s10549-010-0940-x.CrossRefPubMed

73.

Rohan TE, Wang T, Weinmann S, Wang Y, Lin J, Ginsberg M, Loudig O. A miRNA expression signature in breast tumor tissue is associated with risk of distant metastasis. Cancer Res. 2019;79(7):1705–13. https://doi.org/10.1158/0008-5472.CAN-18-2779 (Epub 2019 Feb 13 PMID: 30760517).CrossRefPubMed

74.

Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma L. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014;5:5671. https://doi.org/10.1038/ncomms6671.CrossRefPubMed

75.

Vislovukh A, Kratassiouk G, Porto E, Gralievska N, Beldiman C, Pinna G, El’skaya A, Harel-Bellan A, Negrutskii B, Groisman I. Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer. 2013;108(11):2304–11. https://doi.org/10.1038/bjc.2013.243.CrossRefPubMedPubMedCentral

76.

Tribollet V, Barenton B, Kroiss A, Vincent S, Zhang L, Forcet C, Cerutti C, Périan S, Allioli N, Samarut J, Vanacker JM. miR-135a inhibits the invasion of cancer cells via suppression of ERRα. PLoS One. 2016;11(5):e0156445. https://doi.org/10.1371/journal.pone.0156445.CrossRefPubMedPubMedCentral

77.

Jiang D, Zhou B, Xiong Y, Cai H. miR-135 regulated breast cancer proliferation and epithelial-mesenchymal transition acts by the Wnt/β-catenin signaling pathway. Int J Mol Med. 2019;43(4):1623–34. https://doi.org/10.3892/ijmm.2019.4081.CrossRefPubMedPubMedCentral

78.

Chen X, Lu P, Wang DD, Yang SJ, Wu Y, Shen HY, Zhong SL, Zhao JH, Tang JH. The role of miRNAs in drug resistance and prognosis of breast cancer formalin-fixed paraffin-embedded tissues. Gene. 2016;595(2):221–6. https://doi.org/10.1016/j.gene.2016.10.015.CrossRefPubMed

79.

Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012;6(4):458–72. https://doi.org/10.1016/j.molonc.2012.03.003.CrossRefPubMedPubMedCentral

80.

Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Can Res. 2009;69(6):2195–200. https://doi.org/10.1158/0008-5472.CAN-08-2920.CrossRef

81.

Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601. https://doi.org/10.1038/ncb1722.CrossRefPubMed

Title: MiRNA expression deregulation correlates with the Oncotype DX® DCIS score
Authors: Olivier Loudig
Megan I. Mitchell
Iddo Z. Ben-Dov
Christina Liu
Susan Fineberg
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Published in: Breast Cancer Research / Issue 1/2022
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-022-01558-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Hormone and receptor activator of NF-κB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women

RAB4A GTPase regulates epithelial-to-mesenchymal transition by modulating RAC1 activation

Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin

Breast cancer worry, uncertainty, and perceived risk following breast density notification in a longitudinal mammography screening cohort

Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment

Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer